High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers

Cancer Prevention Research

Volumn 2, Issue 2, 2009, Pages 122-127

  Arun, Banu ^a   Vogel, Kristen J ^b   Lopez, Adriana ^a   Hernandez, Mike ^a   Atchley, Deann ^a   Broglio, Kristine R ^a   Arnos, Christopher I ^a   Meric Bernstam, Funda ^a   Kuerer, Henry ^a   Hortobagyi, Gabriel N ^a   Albarracin, Constance T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Center for Medical Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GROUPS BY AGE; HUMAN; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BREAST TUMOR; CARCINOMA IN SITU; CROSS-SECTIONAL STUDY; GENETICS; MEDULLARY CARCINOMA; MIDDLE AGED; MUTATION; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES;

EID: 63249089822     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0050     Document Type: Article

References (30)

1. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-949 (Pubitemid 29272520)
2. Malone KE, Daling JR, Neal C, et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 2000;88:1393-1402 (Pubitemid 30155177)
3. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324
4. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710
5. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-2816
6. Ford D, Easton DF, Stratton M, et al. The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-689
7. Narod SA, Ford D, Devilee P, et al. Breast Cancer Linkage Consortium. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995;56:254-264
8. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:1529-1531 (Pubitemid 30757427)
9. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-1250
10. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490
11. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646 (Pubitemid 37310920)
12. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-871 (Pubitemid 46638837)
13. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-3614 (Pubitemid 37169224)
14. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-789 (Pubitemid 30159330)
15. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 1998;29:1140-1144 (Pubitemid 28467537)
16. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005;7:R93-100.
17. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-1510
18. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-1268 (Pubitemid 34177432)
19. Komenaka IK, Ditkoff BA, Joseph KA, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004;100:2079-2083
20. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-164 (Pubitemid 32662123)
21. Sun CC, Lenoir G, Lynch H, Narod SA. In situ breast cancer and BRCA1. Lancet 1996;348:408.
22. Adem C, Reynolds C, Soderberg CL, et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 2003;97:1-11. (Pubitemid 36033857)
23. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-1145 (Pubitemid 28380718)
24. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-158 (Pubitemid 28093844)
25. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580-1590 (Pubitemid 39486366)
26. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005;293:964-969 (Pubitemid 40271128)
27. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007;25:642-647 (Pubitemid 350002918)
28. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41-45
29. Hoogerbrugge N, Bult P, Bonenkamp JJ, et al. Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer 2006;42:2492-2498 (Pubitemid 44442941)
30. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003;97:1601-1608 (Pubitemid 36350702)